Noida Chronicle

Brain Metastasis from Breast Cancer Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products

 Breaking News
  • No posts were found

Brain Metastasis from Breast Cancer Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products

March 10
14:57 2023
Brain Metastasis from Breast Cancer Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products

DelveInsight’s, “Brain Metastasis from Breast Cancer Pipeline Insight, 2023,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Brain Metastasis from the Breast Cancer pipeline landscape. It covers the Brain Metastasis from Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Brain Metastasis from Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Brain Metastasis from Breast Cancer Emerging drugs, the Brain Metastasis from Breast Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Brain Metastasis from Breast Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Brain Metastasis from Breast Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Brain Metastasis from Breast Cancer clinical trials studies, Brain Metastasis from Breast Cancer NDA approvals (if any), and product development activities comprising the technology, Brain Metastasis from Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Brain Metastasis from Breast Cancer Pipeline Report

 

  • DelveInsight’s Brain Metastasis from Breast Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Brain Metastasis from Breast Cancer treatment.

 

  • The leading Brain Metastasis from Breast Cancer Companies includes Angiochem Inc, Novartis, Merck Sharp & Dohme Corp., AstraZeneca, Criterium, Inc., Bristol-Myers Squibb, Bayer, Northwest Biotherapeutics, Array BioPharma, and others.

 

  • Promising Brain Metastasis from Breast Cancer Pipeline Therapies includes Efaproxiral, Whole Brain Radiation Therapy (WBRT), Nivolumab, Stereotactic Radiosurgery, ANG1005, GRN1005, Trastuzumab, 18F-FLT, Sorafenib, NKTR-102, Eribulin, BKM120, and others.

 

  • The Brain Metastasis from Breast Cancer Companies and academics are working to assess challenges and seek opportunities that could influence Brain Metastasis from Breast Cancer R&D. The Brain Metastasis from Breast Cancer pipeline therapies under development are focused on novel approaches to treat/improve Brain Metastasis from Breast Cancer.

 

Request a sample and discover the recent breakthroughs happening in the Brain Metastasis from Breast Cancer Pipeline landscape @ Brain Metastasis from Breast Cancer Pipeline Outlook Report

 

Brain Metastasis from Breast Cancer Overview

Central nervous system or brain metastases traditionally occur in 10-16% of metastatic breast cancer patients and are associated with a dismal prognosis. The development of brain metastases has been associated with young age, and tumors that are estrogen receptor negative, Her-2+ or of the basal phenotype. Diagnosis can be done through MRI (magnetic resonance imaging) study of the brain.In rare cases, biopsies are performed to confirm the diagnosis. Neuroimaging, staging, and diagnostic neuropathology can also be done.

 

Brain Metastasis from Breast Cancer Emerging Drugs Profile

 

  • ANG1005: Angiochem

ANG-1005 is a peptide-drug conjugate containing paclitaxel covalently linked to a peptide (Angiopep-2). The drug gains entry into the brain by targeting the LRP-1, which is one of the most highly-expressed receptors on the surface of the Blood brain barrier. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain. A Phase III clinical trial is evaluating ANG-1005 to treat brain metastasis associated with breast cancer.

 

  • Pembrolizumab: Merck Sharp & Dohme

Pembrolizumab is a medication used in the management and treatment of various oncologic conditions. It is in the cancer immunotherapy class of drugs. KEYTRUDA binds to the PD⁠-⁠1 receptor, blocking both immune-suppressing ligands, PD‑L1 and PD‑L2, from interacting with PD⁠-⁠1 to help restore T-cell response and immune response. The drug is currently being evaluated in Phase I/II stage of development for the treatment of patients with Brain Metastases In Breast Cancer Patients.

 

For further information, refer to the detailed Brain Metastasis from Breast Cancer Drugs Launch, Brain Metastasis from Breast Cancer Developmental Activities, and Brain Metastasis from Breast Cancer News, click here for Brain Metastasis from Breast Cancer Ongoing Clinical Trial Analysis

 

Brain Metastasis from Breast Cancer Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Brain Metastasis from Breast Cancer. The companies which have their Brain Metastasis from Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Angiochem.

 

Brain Metastasis from Breast Cancer Pipeline Segmentation

 

Phases

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Route of Administration

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type

 

Molecule Type

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Find out more about Brain Metastasis from Breast Cancer Pipeline Segmentation, Therapeutics Assessment, and Brain Metastasis from Breast Cancer Emerging Drugs @ Brain Metastasis from Breast Cancer Treatment Landscape

 

Scope of the Brain Metastasis from Breast Cancer Pipeline Report

 

  • Coverage- Global

 

  • Brain Metastasis from Breast Cancer Companies- Angiochem Inc, Novartis, Merck Sharp & Dohme Corp., AstraZeneca, Criterium, Inc., Bristol-Myers Squibb, Bayer, Northwest Biotherapeutics, Array BioPharma, and others.

 

  • Brain Metastasis from Breast Cancer Pipeline Therapies- Efaproxiral, Whole Brain Radiation Therapy (WBRT), Nivolumab, Stereotactic Radiosurgery, ANG1005, GRN1005, Trastuzumab, 18F-FLT, Sorafenib, NKTR-102, Eribulin, BKM120, and others.

 

  • Brain Metastasis from Breast Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

  

Dive deep into rich insights for drugs for Brain Metastasis from Breast Cancer Pipeline Companies and Therapies, click here @ Brain Metastasis from Breast Cancer Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Brain Metastasis from Breast Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. ANG1005: Angiochem
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. Drug Name: Company Name
  11. Drug profiles in the detailed report…..
  12. Early stage products (Phase I)
  13. Pembrolizumab: Merck Sharp & Dohme
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Brain Metastasis from Breast Cancer Key Companies
  17. Brain Metastasis from Breast Cancer Key Products
  18. Brain Metastasis from Breast Cancer- Unmet Needs
  19. Brain Metastasis from Breast Cancer- Market Drivers and Barriers
  20. Brain Metastasis from Breast Cancer- Future Perspectives and Conclusion
  21. Brain Metastasis from Breast Cancer Analyst Views
  22. Brain Metastasis from Breast Cancer Key Companies
  23. Appendix

 

Got Queries? Find out the related information on Brain Metastasis from Breast Cancer Mergers and acquisitions, Brain Metastasis from Breast Cancer Licensing Activities @ Brain Metastasis from Breast Cancer Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/